Stockreport

Why Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii Arbitration [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF metastatic prostate cancer, securing a US$240,000,000 upfront payment, a US$75,000,000 equity investment at US$10.36 per share, a near-term US$20,000,000 milestone, pote [Read more]